Bavarian Nordic awarded $9 million Janssen contract

Bavarian Nordic recently signed a $9 million contract with Crucell Holland B.V., a Janssen Pharmaceutical Companies of Johnson & Johnson subsidiary, to further develop a possible Ebola vaccine boost regimen consisting of Bavarian Nordic's MVA-BN(R) Filo and Janssen's Ad26.ZEBOV. 

The contract is being funded as part of a U.S. Biomedical Advanced Research and Development Authority (BARDA) award that Janssen received. It includes options for up to $24 million for implementing the process development and formulation should the regimen succeed in clinical trials.

"We are very pleased to strengthen our collaboration with Janssen on the accelerated development of the prime-boost Ebola vaccine regimen," Paul Chaplin, president and CEO of Bavarian Nordic, said. "More importantly, it is encouraging that the U.S. government -- through BARDA, with whom we have worked for over a decade -- recognizes the potential of this vaccine to build international preparedness for current and future Ebola outbreaks."

Janssen has initiated clinical studies of the prime-boost in Europe and Africa through an accelerated development program.

In preclinical studies conducted by the National Institutes of Health, the MVA-BN Filo and Ad26.ZEBOV vaccine regimen was found to be highly successful in protecting against the Ebola virus. 

Organizations in this Story

Bavarian Nordic National Institutes of Health

Want to get notified whenever we write about any of these organizations ?
Next time we write about any of these organizations, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.